ニュース

Hims & Hers Health reported first-quarter 2026 results with revenue of US$608.1 million, up from US$586.01 million a year earlier, but moved from net income of US$49.49 million to a net loss of US$92.12 million as earnings per share turned from profit to a US$0.40 loss. The company attributed much of the earnings setback to restructuring costs and margin pressure tied to its pivot from compounded to branded GLP-1 weight-loss medications, even as it raised revenue guidance for both the second...

The S&P 500 Index ($SPX ) (SPY ) today is down -0.44%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.74%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.72%. June E-mini S&P futures (ESM26 ) are down -0.38%, and June E-mini Nasdaq futures...

Hims & Hers slashed its profitability outlook for 2026. The news sent Hims stock into free fall Tuesday morning.

US equity futures were lower pre-bell Tuesday as the standoff continued in the Middle East, with the

Shares of Hims & Hers (NYSE:HIMS) dropped roughly 16% in premarket trading on Tuesday after the company reported an unexpected first-quarter loss, missing Wall Street earnings expectations as weaker performance in its U. S.

Revenue outlook rises as Wegovy demand accelerates sharply

Hims & Hers missed on both the top and bottom line

News of the day for May 12, 2026

Hims & Hers stock sinks as higher costs weighed on the health platform's quarterly results.

Hims & Hers stock sinks as higher costs weighed on the health platform's quarterly results.

The telehealth company posted a net loss of $92 million in the first quarter as its shift away from compounded weight loss drugs drove up costs

Trump’s China summit threatens the AI boom, Ford gets into the energy storage business, Hims & Hers posts a surprise loss, and more news to start your day.

Intel and Micron shares falls as investors opt to lock in profits following a breakneck rally in chip stocks.

↗️ Venture Global (VG): The liquefied-natural-gas exporter, which stands to benefit from the closure of the Strait of Hormuz, is due to report results this morning, potentially shedding light on the strength of demand.

Despite restructuring costs, Hims & Hers Health Inc (HIMS) reports robust international growth and raises 2026 revenue outlook.

Hims & Hers Health (NYSE:HIMS) reported first-quarter 2026 revenue growth and raised its full-year revenue outlook, while executives said a strategic shift in the company’s weight-loss business is creating short-term margin pressure and volatility in GAAP results. On the company’s earnings call

By Amina Niasse and Siddhi Mahatole May 11 (Reuters) - Hims & Hers Health missed Wall Street estimates for first-quarter revenue and posted a surprise loss on Monday, as the telehealth company's shift

Hims & Hers Health (HIMS) delivered earnings and revenue surprises of -519.58% and -1.86%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Bronstein, Gewirtz & Grossman, LLC has launched a legal investigation into Hims & Hers Health's corporate practices. The probe focuses on potential wrongdoing by certain officers and directors relating to events before April 2025. The review is aimed at assessing possible impacts on shareholder interests and corporate governance at NYSE:HIMS. For investors watching Hims & Hers Health, NYSE:HIMS, the new legal investigation arrives after a period of sharp share price moves. The stock closed...

The telehealth platform posted a quarterly loss of $92.1 million, driven by higher expenses, including those tied to operations, technology and general and administrative functions.

Investing.com -- Hims & Hers missed first-quarter earnings estimates, posting a loss as weakness in its American operations offset gains overseas.

Shares of Hims & Hers Health sank late Monday after the company underperformed first-quarter earnings and revenue expectations, surprising Wall Street with a quarterly loss. The telehealth provider, which made a name for itself in the business of weight-loss drugs, posted a first-quarter loss of 40 cents a share, compared with profit of 20 cents a share a year ago. Wall Street was looking for a profit of 3 cents a share.

Telehealth company Hims & Hers Health (NYSE:HIMS) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 3.8% year on year to $608.1 million. On the other hand, next quarter’s outlook exceeded expectations with revenue guided to $690 million at the midpoint, or 6% above analysts’ estimates. Its GAAP loss of $0.40 per share was significantly below analysts’ consensus estimates.

HIMS broadens its digital health platform with Labs, menopause and testosterone care, global acquisitions and a Novo Nordisk GLP-1 tie-up.

Markets Await Key Inflation Data This Week.

We'll see new inflation data the same week the Senate is likely to confirm Kevin Warsh - an advocate of cutting interest rates - as Fed Chair.

The benchmark US stock measures were pointing lower before the opening bell Monday as the US rejecte

The pace of first quarter earnings reports eases this week as economic data takes center stage, but investors will still be on the lookout for results from a handful of big corporations.